56,861 Shares in Pacific Biosciences of California, Inc. (NASDAQ:PACB) Purchased by XTX Topco Ltd

XTX Topco Ltd purchased a new stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) in the third quarter, Holdings Channel.com reports. The firm purchased 56,861 shares of the biotechnology company’s stock, valued at approximately $97,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PACB. Creative Planning boosted its position in shares of Pacific Biosciences of California by 30.8% during the third quarter. Creative Planning now owns 32,409 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 7,629 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in Pacific Biosciences of California by 4.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 235,308 shares of the biotechnology company’s stock valued at $322,000 after acquiring an additional 9,516 shares in the last quarter. Water Island Capital LLC boosted its holdings in Pacific Biosciences of California by 91.1% during the 2nd quarter. Water Island Capital LLC now owns 20,000 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 9,537 shares during the last quarter. Atria Investments Inc grew its stake in shares of Pacific Biosciences of California by 85.7% in the 3rd quarter. Atria Investments Inc now owns 21,968 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 10,138 shares in the last quarter. Finally, Impact Partnership Wealth LLC raised its holdings in shares of Pacific Biosciences of California by 44.7% in the third quarter. Impact Partnership Wealth LLC now owns 39,169 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 12,093 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on PACB shares. StockNews.com upgraded shares of Pacific Biosciences of California to a “sell” rating in a report on Tuesday, November 12th. UBS Group lowered Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 target price for the company. in a report on Monday, November 11th. Piper Sandler lifted their price target on Pacific Biosciences of California from $2.00 to $2.50 and gave the stock a “neutral” rating in a report on Monday, November 11th. Finally, Scotiabank reduced their price objective on Pacific Biosciences of California from $7.00 to $6.00 and set a “sector outperform” rating for the company in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $2.95.

Pacific Biosciences of California Stock Up 2.1 %

Shares of NASDAQ PACB opened at $1.97 on Friday. The company has a debt-to-equity ratio of 1.97, a current ratio of 9.74 and a quick ratio of 8.64. The stock has a market capitalization of $539.51 million, a PE ratio of -1.35 and a beta of 1.95. Pacific Biosciences of California, Inc. has a one year low of $1.16 and a one year high of $10.65. The business’s fifty day moving average price is $2.00 and its 200-day moving average price is $1.77.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.